

WMSHP Newsletter



March 2015

Contents

President's message	2
ASHP Member Featured in NPR Story about Pharmacists' Role in Reduced Readmissions	3
New Oral Drug Approval for Multiple Myeloma: Panibinostat	4, 5
2014 ASHP Midyear pic	6
Distinguished Achievement Award in Pharmacy Practice	7
WMSHP Residents/Fellows Seminar	
January Kickoff meeting	9, 10
ASHP Delegate News Update	11
Meetings	3, 4
Save the Date	3

Wishing everyone a Happy Spring season! There are many upcoming activities planned for our members during this year in order to mingle and enjoy the weather together. Also, with more support from our government leaders in regards to Provider status, this will be an exciting year for the development of our profession. We continue to encourage our members to become actively involved in all levels of the society varying from leadership to committee involvement. We are only as strong as our members. We would like to thank you all for your support throughout the years and the upcoming ones.

*Monique, ASHP Delegate
2014 – 2016*



PRESIDENT'S MESSAGE

WMSHP,

The Pharmacy profession has entered an exciting era between 2014 and 2015 with the introduction in Congress of pharmacists' provider status legislation. Support for this legislation is gaining momentum both in the communities we serve and in Congress. Per Dr Paul Abramowitz, ASHP CEO, in the near future a companion bill is anticipated to be introduced in the Senate to accompany the "Pharmacy and Medically Underserved Areas Enhancement Act" introduced by Congress. Please continue to reach out to your members of Congress to help achieve this important goal.

Meanwhile, WMSHP Committee members are working hard to provide continuing education credits, disease states presentations and fun activities for the membership.

The Programming Committee is proud to be collaborating with NIH to present Pharmacotherapy Frontiers on April 25, 2015. The Spring and Fall all day 6-CE Conferences are scheduled for May 30, 2015 and September 19, 2015. We are honored to welcome guest speakers who are experts in their respective fields. In October 2015 we are also collaborating with Pharmacy Learning Network (PLN) for a 7-CE Conference. In addition to all the continuing education credits, we are providing Non-CE Disease State Presentations monthly except during CE months.

The Membership Committee is busy preparing fun activities such as a Summer Picnic and a Fall trip to a Winery. They are also engaged in recruiting new members and establishing a student track. Please join this committee and help us reach out to students, residents, technicians and pharmacists.

Our ASHP Delegates Monique Bonhomme and John Quinn are busy preparing to go to the Regional and Summer ASHP Delegate meetings with suggestions for new resolutions.

Please join our various Committees so that we may continue to strengthen our society, collaborate with other societies and student organizations, and reach our professional goals in healthcare.

I hope to see you soon during our various events. Thank you so much for being members of our fine society.

Wafaa

2015 - SAVE THE DATE - CE EVENTS

April 25, 2015

Pharmacotherapy Frontiers: NIH in collaboration with WMSHP

October 2015

Pharmacy Learning Network (PLN)

=====

ASHP Member Featured in NPR Story about Pharmacists' Role in Reduced Readmissions

Article Demonstrates Need for Pharmacist Care for the Medically Underserved

1/30/2015

Pharmacists at the Cleveland Clinic are helping to reduce patient readmissions, thereby avoiding Medicare fines, by providing critical medication counseling and direct patient care services, according to a new article published by National Public Radio.

ASHP member Katie Greenlee, Pharm.D., BCPS, clinical specialist-cardiology and program director of the Clinic's ASHP-accredited PGY1 Pharmacy Practice Residency, was featured in the article as she worked with cardiology patients to help them understand how and when to take their medications effectively.

The story went on to profile other Cleveland hospitals serving many of the area's poorer patients that could benefit from pharmacists' medication management services.

"This story perfectly demonstrates how the new provider status legislation introduced in Congress this week, if enacted into law, could significantly improve patient outcomes," said ASHP CEO Paul W. Abramowitz, Pharm.D., Sc.D. (Hon.), FASHP. "Pharmacists are key to affordable, effective patient care."

- See more at: <http://www.ashp.org/menu/News/NewsCapsules/>

Save the Date



WMSHP Spring Meeting
National 4-H Youth Conference
May 30, 2015
Chevy Chase, MD

ASHP Summer Meeting &
Exhibition
June 6 - 10, 2015
Denver, Colorado



WMSHP Fall Meeting
National 4-H Youth Conference
September 19, 2015
Chevy Chase, MD

2015 Midyear Clinical Meeting and
Exhibition
December 6 - 10, 2015
New Orleans, LA

New Oral Drug Approval for Multiple Myeloma: Panibinostat

Rosalynnda Uy, Pharm.D, BCPS
PGY-2 Oncology Pharmacy Resident
Walter Reed National Military Medical Center
Bethesda, MD

Multiple myeloma is a blood cancer that arises from plasma cells found in the bone marrow and even with treatment remains an incurable disease. There are approximately 24,000 new diagnoses each year associated with 11090 deaths in 2014. This accounts for roughly 1% of all cancers and 13% of hematologic cancers world-wide.¹ The affected plasma cells overcrowd the healthy cells within the bone marrow and then circulate to other parts of the body. This can quickly lead to a weakened immune system, anemia, bone and kidney problems.¹

Many treatment regimens are available for the standard front-line therapy for induction phase of multiple myeloma. Regimen selection is based upon risk-stratification that includes independent molecular cytogenetic markers, age, disease aggressiveness, and transplant status. Patients with a standard risk myeloma have a median overall survival of approximate 6-7 years while those with high risk disease experience a much shorter overall survival of less than 2 to 3 years despite autologous stem-cell transplantation. If the patient's disease progress through therapy, an alternate regimen will be tried until the disease progresses or there is an acceptable response.³

On February 23, 2015, the U.S. Food and Drug Administration approved Farydak (panobinostat) for the treatment of multiple myeloma. Panobinostat received priority review in the accelerated approval program due to nature of the life-threatening disease as well as novel mechanism of action. Histone deacetylases (HDACs) are enzymes that assist with over-development of plasma cells in multiple myeloma. Panobinostat inhibits the HDACs activity causing the cell to die. The indication is in combination with bortezomib and dexamethasone, with at least 2 prior regimens containing bortezomib and an immunomodulatory agent.⁵

The accelerated FDA approval of panobinostat was based on a Phase 3 multi-center, randomized, double-blind trial where 768 patients were enrolled from Jan 21, 2010 to Feb 29, 2012 (Clinical Trial NCT01023308).

New Oral Drug Approval for Multiple Myeloma: Panobinostat (continued)

About half the patients were randomly assigned to panobinostat, bortezomib and dexamethasone versus the control group of placebo, bortezomib and dexamethasone. The median progression free survival was 11.99 months in the study arm versus 8.08 months in the control group. The proportion of patients with a complete or near complete response was significantly higher in the panobinostat group at 27.6% versus 15.7%. The most common grade 3 or 4 adverse reactions included diarrhea, asthenia or fatigue and peripheral neuropathy. Twice as many patients experienced a hemorrhage with 16 (4%) in the panobinostat group versus 9 (2%) in the placebo.^{5,7} There are no contraindications for administering panobinostat but several warnings and precautions are noted. The product has a black box warning for severe diarrhea as well as severe and fatal cardiac ischemic events, arrhythmias and ECG changes. Due to the risk of hemorrhage, active monitoring of platelet counts is advised. Monitor hepatic enzymes and adjust dose for possible hepatotoxicity. Panobinostat is associated with fetal harm and should be avoided in pregnancy. The FDA approval comes with a Risk Evaluation and Mitigation Strategy entailing a communication plan for health care professionals regarding risks and minimization options.

Panobinostat is available as a 10 mg, 15 mg and 20 mg capsules. Initial dosing is 20 mg by mouth every other day 3 times a week on days 1, 2, 5, 6, 10 and 12 of weeks 1 and 2 of a 21 days cycle for 8 cycles. If a patient continues to experience significant benefit, panobinostat may be continued for 8 additional cycles.⁸

References available upon request

2014 ASHP MIDYEAR CLINICAL MEETING



Dr. Vaiyapuri Subramaniam, PharmD, attended an Invitational evening program function to honor all ASHP State Affiliate Society Presidents and Representatives at the 2014 ASHP Midyear Clinical Meeting held in Anaheim, CA

2015 APhA ANNUAL MEETING - March 27th - 30th



Distinguished Achievement in Pharmacy Practice Award to Dominic Solimando by American Pharmacists Association (APhA):

WMSHP congratulates member Dominic Solimando Jr. MA, BCOP, FAPhA, FASHP, who received the Distinguished Achievement in Pharmacy Practice Award by APhA. This award was presented on Sunday - March 29th, during the 2015 APhA Annual Meeting to outstanding pharmacists for their achievements in the field of pharmacy practice and management, the pharmaceutical sciences and the development of student pharmacists.

Dominic is President of Oncology Pharmacy Services, Inc.

2015 - WMSHP Pharmacy Residents/Fellows Seminar - April 2nd



WMSHP Pharmacy Residents/Fellows Seminar held at Sibley Memorial Hospital-Johns Hopkins Medicine on April 2nd - led by Pamela Smith, Director, Medical Outcomes Specialist, Global Medical Division, Pfizer, Inc.:

PGY1 residents attended:

Lynette Badu from Howard University Hospital, Andre Allen from Howard University Hospital, Natalie Berner from Howard University Hospital, Valerie Hoffman from Peninsula Regional Medical Center, Samantha Bryant from Peninsula Regional Medical Center, Norm Fenn from Children's National Medical Center, Paul Norris from Sibley-Memorial Hospital-Johns Hopkins Medicine, Charrell Porter from Sibley Memorial-Johns Memorial Hospital

2015 JANUARY KICKOFF MEETING - PAPARAZZI PICS



2015 JANUARY KICKOFF MEETING - PAPARAZZI PICS - Welcome our new Board members



ASHP Delegate News**Update:**

Elected WMSHP Delegates: Monique Bonhomme and John Quinn have each submitted a resolution to the House of Delegates for review.

Regional Delegate Conference (RDC) will be attended by both delegates in Baltimore, MD in May, 2015.

Summer Meeting will be held in June in Denver, Colorado where the ASHP Delegates will convene.

WMSHP Committees

Interested in becoming actively involved in WMSHP?

Join and participate in one or more of our Committees

Finance	Legislative
Membership	Programming (monthly meetings)
Nominations	Publications (newsletters, website)

****Send email with interest to Committee Chairs posted on www.wmshp.org****

OFFICERS*President*

Wafaa Abou-Zeineddine
wafaawmshp@gmail.com

President-elect

Vaiyapuri Subramaniam
vpuris@gmail.com

Secretary

Sarah Kelly
sarahkellywmshp@gmail.com

Treasurer

Min Hee Kang
kangminhee0205@gmail.com

Board Members

Meriam Senay
mzemenue@gmail.com

Leon Vandenburg
l.vandenberg@verizon.net

ASHP Delegates

Monique Bonhomme
monique.wmshp@gmail.com

John Quinn
john.quinn@fda.hhs.gov